Literature DB >> 8478038

Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats.

R Larivière1, G Thibault, E L Schiffrin.   

Abstract

Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide produced in the endothelium of blood vessels that may play an important role in the control of local blood flow and could be involved in the pathogenesis of hypertension. We investigated immunoreactive ET-1 (ir-ET-1) levels in acid extracts from blood vessels of deoxycorticosterone acetate (DOCA)-salt and spontaneously hypertensive rats. We found that segments of thoracic aorta and the mesenteric vascular bed contain significantly more ir-ET-1 (11.84 +/- 0.84 and 17.30 +/- 1.89 fmol, respectively) than uninephrectomized control rats (1.78 +/- 0.20 and 9.19 +/- 0.63 fmol, respectively; p < 0.001). High performance liquid chromatography showed that ir-ET-1 of blood vessels of DOCA-salt hypertensive rats eluted in the same position as synthetic ET-1. Significantly increased ir-ET-1 was localized by immunohistochemistry in endothelial cells of aorta and large and small mesenteric arteries of DOCA-salt hypertensive rats. In contrast to the latter, in spontaneously hypertensive rats, vascular content of ir-ET-1 was similar to that of blood vessels of Wistar-Kyoto control rats, at both 6 and 16 weeks of age. High levels of vascular ET-1 may explain the downregulation of vascular endothelin receptors previously described in DOCA-salt hypertensive rats. Furthermore, this suggests that ET-1 may be involved in the maintenance of high blood pressure in mineralocorticoid hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478038     DOI: 10.1161/01.hyp.21.3.294

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

Review 1.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 2.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Calcium antagonists and endothelial function: focus on nitric oxide and endothelin.

Authors:  T Godfraind; S Salomone
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

5.  Role of aldosterone in the remnant kidney model in the rat.

Authors:  E L Greene; S Kren; T H Hostetter
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium.

Authors:  P Laurant; A Berthelot
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

Review 7.  Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

8.  Role of endothelin and vasopressin in DOCA-salt hypertension.

Authors:  M Yu; V Gopalakrishnan; J R McNeill
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 9.  Endothelin and the renal microcirculation.

Authors:  Zhengrong Guan; Justin P VanBeusecum; Edward W Inscho
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

10.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.